Case Study: an emerging biotech company launches its first oncology orphan drug with Axtria's analytics-driven incentive plan

Emerging Biotech Company achieves 100% problem-free execution with Axtria

The customer, an emerging biotech company, faced the challenge of designing a go-to-market strategy and incentive plan for its first oncology orphan drug launch. Lacking advanced analytics and commercial operations functions, they required a consultative approach to avoid delays and sales productivity issues. They partnered with the vendor Axtria for its incentive compensation expertise.

Axtria implemented a multi-pronged solution featuring analytics-driven market segmentation, unified sales goals, and fair rep-level competitions. This approach ensured a problem-free execution for the emerging biotech company, achieving full buy-in from sales leadership and payout predictability. Axtria's solution accelerated the go-to-market process, enabling the successful and timely launch of the orphan drug.